ARCHIVES

In Brief: Minority Based CCOP Workshop Planned; NCI Changes To 800-4-CANCER On Levamisole

This article is from The Cancer Letter archive.

Vol. 15 No. 31 | August 4, 1989

Download PDF Visit The Full Archive

Related Articles

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

NCI Cooperative Group, Cancer Center Trials Listed

February 27, 2009

GAO Report Finds Increase in Self-Referred Pathology Services

August 9, 2013

Sharfstein To Leave FDA

January 7, 2011

Afinitor Suspension Approved For Rare Pediatric Brain Tumor

August 31, 2012

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

June 21, 2002